论文部分内容阅读
目的:观察甲磺酸伊马替尼治疗慢性粒细胞白血病进展期患者的临床疗效。方法:选择31例慢性粒细胞白血病进展期患者,分为伊马替尼治疗组(治疗组12例)和对照组(19例),分别给予甲磺酸伊马替尼和联合化疗治疗,观察并比较2组间血液学有效率及不良反应耐受性等指标的变化。结果:治疗组总的血液学有效率为41.7%,对照组总的血液学有效率为5.3%,2组间比较差异有统计学意义(P<0.05)。治疗组患者药物不良反应发生率较对照组轻且容易耐受。结论:甲磺酸伊马替尼对进展期慢性粒细胞白血病患者有较好的疗效,且毒副反应轻,病人耐受性好。
Objective: To observe the clinical efficacy of imatinib mesylate in the treatment of advanced patients with chronic myeloid leukemia. Methods: Thirty-one patients with advanced chronic myeloid leukemia were enrolled and divided into imatinib treatment group (12 cases) and control group (19 cases). The patients were treated with imatinib mesylate and combination chemotherapy, respectively The changes of hematological efficiency and adverse reaction tolerance were compared among the two groups. Results: The total effective rate of hematology was 41.7% in the treatment group and 5.3% in the control group. The difference between the two groups was statistically significant (P <0.05). The incidence of adverse drug reactions in the treatment group was lighter and easier to tolerate than that in the control group. Conclusion: Imatinib mesylate has a good curative effect on patients with advanced chronic myelogenous leukemia with mild side effects and good patient tolerance.